VALEANT PHARMACEUTICALS INTL's ticker is VRX and the CUSIP is 91911K102. A total of 487 filers reported holding VALEANT PHARMACEUTICALS INTL in Q2 2014. The put-call ratio across all filers is 0.91 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $14,487,000 | +103.6% | 910,000 | +1200.0% | 1.04% | +51.3% |
| Q4 2015 | $7,116,000 | +33.0% | 70,000 | +133.3% | 0.69% | +47.8% |
| Q3 2015 | $5,351,000 | -51.8% | 30,000 | -40.0% | 0.47% | -40.9% |
| Q2 2015 | $11,107,000 | +51.8% | 50,000 | +35.7% | 0.79% | +35.3% |
| Q1 2015 | $7,316,000 | -50.8% | 36,835 | -64.6% | 0.58% | -42.9% |
| Q4 2014 | $14,883,000 | +8.0% | 104,000 | -1.0% | 1.02% | +7.5% |
| Q3 2014 | $13,776,000 | -47.2% | 105,000 | -49.3% | 0.95% | -30.7% |
| Q2 2014 | $26,107,000 | +204.7% | 207,000 | +218.5% | 1.37% | +315.1% |
| Q1 2014 | $8,569,000 | +46.0% | 65,000 | +30.0% | 0.33% | +31.9% |
| Q4 2013 | $5,870,000 | +60.7% | 50,000 | +42.9% | 0.25% | +37.2% |
| Q3 2013 | $3,652,000 | -15.1% | 35,000 | -30.0% | 0.18% | -24.1% |
| Q2 2013 | $4,304,000 | – | 50,000 | – | 0.24% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Brave Warrior Advisors | 5,577,892 | $994,984,000 | 31.62% |
| Ruane, Cunniff & Goldfarb | 33,922,192 | $6,051,041,000 | 31.06% |
| LeVasseur Capital Partners LLC | 162,394 | $28,968,000 | 29.76% |
| FARLEY CAPITAL L.P. | 192,130 | $34,272,000 | 27.18% |
| Pershing Square Capital Management | 19,473,933 | $3,473,760,000 | 24.90% |
| Arrow Capital Management, LLC | 109,461 | $19,525,000 | 16.53% |
| Marble Arch Investments | 1,196,900 | $213,503,000 | 16.43% |
| Tesuji Partners | 1,368,040 | $244,414,000 | 15.82% |
| ValueAct Holdings | 14,994,261 | $2,674,676,000 | 15.55% |
| Hound Partners | 3,898,648 | $695,441,000 | 15.04% |